v3.26.1
Investments accounted for using the equity method (Details)
€ in Thousands
 12 Months Ended
Dec. 30, 2025
EUR (€)
Dec. 31, 2025
EUR (€)
item
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Investments        
Equity book value limit   € 1,000    
Evotec's share of earnings limit   € 1,000    
Number of investments classified as significant | item   1    
Number of investments classified as insignificant | item   5    
Balance at beginning   € 2,138 € 3,071  
Investment   3,576 3,379  
Share of profit/(loss) in associate   (1,085) (4,312)  
Net book value at end   4,629 2,138 € 3,071
Current assets   762,945 681,964  
Non-current assets   951,000 1,230,538  
Current liabilities   368,074 344,585  
Non-current liabilities   532,167 615,392  
Revenues from 01 Jan to 31 Dec   788,373 796,967 781,426
Net income (loss) 1 Jan to 31 Dec   (103,517) (196,078) (83,913)
Autobahn Labs LLC        
Investments        
Investment     1,378  
Share of profit/(loss) in associate     (1,378)  
Centauri Therapeutics GmbH        
Investments        
Balance at beginning   1,264 2,179  
Investment   3,576    
Share of profit/(loss) in associate   (634) (916)  
Net book value at end   4,206 1,264 2,179
Current assets   14,127 383  
Non-current assets   239 299  
Current liabilities   233 245  
Revenues from 01 Jan to 31 Dec   4,837 1  
Net income (loss) 1 Jan to 31 Dec   (3,915) (4,483)  
Dark Blue Therapeutics Ltd        
Investments        
Gain on sale of associate investments € 12,125      
Current assets     291  
Non-current assets     9,047  
Current liabilities     981  
Net income (loss) 1 Jan to 31 Dec     (3,115)  
EIR Biotherapies        
Investments        
Balance at beginning   873    
Investment     1,022  
Share of profit/(loss) in associate     (149)  
Net book value at end     873  
Current assets     634  
Non-current assets     1,752  
Current liabilities     187  
Non-current liabilities     2  
Net income (loss) 1 Jan to 31 Dec     (167)  
Quantro Therapeutics GmbH        
Investments        
Balance at beginning     892  
Share of profit/(loss) in associate     (892)  
Net book value at end       € 892
Current assets     1,121  
Non-current assets     549  
Current liabilities     2,072  
Non-current liabilities     4,325  
Revenues from 01 Jan to 31 Dec     1,294  
Net income (loss) 1 Jan to 31 Dec     (3,974)  
Topas Therapeutics GmbH        
Investments        
Investment     977  
Share of profit/(loss) in associate     (977)  
Current assets     7,560  
Non-current assets     972  
Current liabilities     548  
Net income (loss) 1 Jan to 31 Dec     (9,418)  
Insignificant investments        
Investments        
Balance at beginning   874    
Share of profit/(loss) in associate   (451)    
Net book value at end   423 874  
Insignificant investments        
Investments        
Balance at beginning   € 2    
Investment     2  
Net book value at end     € 2